Lithium citrate

• Description :

  Lithium citrate is a lithium supplement that reduces excess brain N-acetylaspartate (NAA) in Canavan disease. Canavan disease is an autosomal recessive leukodystrophy caused by mutations in the aspartate acylase (ASPA) gene, which catalyzes the hydrolysis of N-acetylaspartate (NAA) to acetate and aspartate[1].

• Product Name Alternative :

  Litarex

• UNSPSC :

  12352211

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Others

• Type :

  Reference compound

• Related Pathways :

  Others

• Applications :

  Neuroscience-Neuromodulation

• Field of Research :

  Neurological Disease

• Assay Protocol :

  https://www.medchemexpress.com/lithium-citrate.html

• Purity :

  98.0

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(CC(C(O[Li])=O)(CC(O[Li])=O)O)O[Li]

• Molecular Formula :

  C6H5Li3O7

• Molecular Weight :

  209.92

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Mitra Assadi, et al. Lithium citrate reduces excessive intra-cerebral N-acetyl aspartate in Canavan disease. Eur J Paediatr Neurol. 2010 Jul;14 (4) :354-9.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Launched

• CAS Number :

  [919-16-4]